A single-center, open-label, single-arm, phase I study with dose expansion cohort of sacituzumab govitecan in combination with cisplatin for patients with platinum sensitive recurrent ovarian and ...
Detailed price information for Oncolytics Biotech Inc (ONCY-Q) from The Globe and Mail including charting and trades.
Detailed price information for Cardiff Oncology Inc (CRDF-Q) from The Globe and Mail including charting and trades.
A phase III randomized trial of eribulin (E) with gemcitabine vs standard of care (SOC) for patients (pts) with metastatic urothelial carcinoma (mUC) refractory to or ineligible for PD/PDL1 antibody ...
We conducted a phase 3, double-blind, double-dummy, randomized, controlled trial involving adults with acute, nonarteritic central retinal artery occlusion who had symptom onset within 4.5 hours ...
Morning Overview on MSN
An SGLT2 pill protected the kidneys of teenagers with type 1 diabetes in a new trial
Teenagers with type 1 diabetes now have the first randomized trial evidence that an SGLT2 inhibitor can protect their kidneys ...
The authors sought to understand the differential impact of payer-led community-based care management approaches on stakeholder-oriented outcomes for publicly insured adults with multiple chronic ...
Review authors suggested guidelines to help in standardizing future lupus nephritis studies. Heterogeneity in lupus nephritis (LN) trial design substantially hinders interpretation of studied drugs’ ...
10d
Mesoblast Achieves Target of 300 Treated Patients in Pivotal Phase 3 Trial for Chronic Low Back Pain
Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has achieved its target of at least 300 patients treated in ...
Tesamorelin can selectively reduce visceral fat, as demonstrated in RCTs. But the real story is what it reveals about ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results